ipharmacenter Consulting services

AstraZeneca has introduced K+ Connect, a nationwide initiative aimed at improving the management of hyperkalemia among patients with heart failure (HF) and chronic kidney disease (CKD) in India. The program brings together 33 leading tertiary care institutions to promote coordinated, multidisciplinary care and establish a network of Centers of Excellence dedicated to tackling hyperkalemia. Also read: NICE recommends Spinraza and Evrysdi for routine use; Imfinzi for aggressive

CDSCO Clears Durvalumab AstraZeneca received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) for the use of durvalumab in combination with FLOT chemotherapy, a regimen including fluorouracil, leucovorin, oxaliplatin, and docetaxel, as a perioperative treatment for adults with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. This marks the first and only immunotherapy-based perioperative regimen to demonstrate a survival a

Sun Pharmaceutical Industries has secured approval from the Drugs Controller General of India (DCGI) to manufacture and commercialize a generic variant of semaglutide injection in the domestic market. The therapy, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, is intended for long-term weight management in adults when combined with a healthy diet and regular physical activity. The company will introduce its generic semaglutide injection under the b

Sun Pharma Launches ILUMYA in India Sun Pharma has unveiled its globally recognized innovative medication, ILUMYA (Tildrakizumab), now available in India for managing moderate-to-severe plaque psoriasis. This advanced biologic therapy has garnered extensive acceptance among dermatologists in the United States and internationally as a reliable and safe option for treating this condition. Also read: Top pharmaceutical companies by revenues in 2025 Long-Term Efficacy of ILUMYA

AstraZeneca has received approval from the Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of...

Dr. Reddy’s Laboratories has introduced Toripalimab in India, marking it as the first and only immuno-oncology therapy approved for...

Sanofi India announced the receipt of marketing authorization for Beyfortus (nirsevimab) from the Central Drugs Standard Control...

May 21, 2024 Glenmark and BeiGene Collaborate to Market and Distribute Tislelizumab and Zanubrutinib in India Key Points: Tislelizumab:...

19th January, 2024 Tirzepatide Recommended alongside dietary adjustments and physical activity to enhance blood sugar management in...

January 03, 2024 AstraZeneca India Unveils Trastuzumab Deruxtecan for HER2-Positive Metastatic Cases AstraZeneca India has officially...

September 30, 2023 AstraZeneca received approval from CDSCO for palivizumab to prevent RSV infection. AstraZeneca approved palivizumab, a...

September 26, 2023 Cipla initiated drone services to deliver medicines to difficult-to-reach terrains. Cipla Limited has unveiled an...

A study was conducted by the Department of Pharmaceuticals in India to assess the skills required for the Indian pharmaceutical industry....